4 results
To compare the safety and efficacy of the Tack Endovascular System* in subjects with peripheral artery disease (PAD) to a pre-defined performance goal (PG).
To determine the safety and tolerability of L19-IL2 combined with SABR.
The main aim is to test whether cetuximab-IRDye800CW is a reliable marker for residual tumor remnants in resection margins after surgical removal of head and neck cancer. To increase the specificity of cetuximab-800CW, a specific frozen section can…
The design will be a prospective, single center phase I feasibility and dose finding study in patients with high-grade glioma, to establish the safety, feasibility, and optimal dosage of Cetuximab-IRDye800CW for fluorescence guided surgery, in…